Lubner David Charles
Insider CIK 1572000 · CBIO Director · TTPH SVP and CFO, 10% owner · RARX Executive VP and CFO · NITE Director · ACLX Director · PNT Director · GMTX Director · VOR Director · DYN Director · CRGX Director · BRVE Director
Trades across companies
| Ticker | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-07 | 55,555 | $18.00 | $1000.0K | 55,555 | SEC↗ |
| BRVE Braveheart Bio, Inc. | P Buy | 2026-08-07 | 2026-08-07 | 55,555 | $18.00 | $1000.0K | 55,555 | SEC↗ |
| BRVE Braveheart Bio, Inc. | A Award deriv | 2026-08-05 | 2026-08-07 | 60,000 | — | $0 | 60,000 | SEC↗ |
| BRVE Braveheart Bio, Inc. | A Award deriv | 2026-08-05 | 2026-08-07 | 60,000 | — | $0 | 60,000 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2026-06-05 | 2026-06-09 | 35,152 | — | $0 | 35,152 | SEC↗ |
| CBIO CRESCENT BIOPHARMA, INC. | A Award deriv | 2026-06-02 | 2026-06-03 | 11,050 | — | $0 | 11,050 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 61,538 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 8,011 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 11,459 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 9,174 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 31,794 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 59,405 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | D To issuer deriv | 2026-04-28 | 2026-04-28 | 13,626 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | U Tender | 2026-04-28 | 2026-04-28 | 21,659 | — | $0 | 0 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | G Gift | 2026-04-24 | 2026-04-28 | 53,625 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | M Exercise deriv | 2026-01-20 | 2026-01-20 | 6,000 | — | $0 | 59,405 | SEC↗ |
| ACLX Arcellx, Inc. | M Exercise | 2026-01-20 | 2026-01-20 | 6,000 | $6.28 | $37.7K | 27,659 | SEC↗ |
| ACLX Arcellx, Inc. | S Sale | 2026-01-20 | 2026-01-20 | 6,000 | $75.00 | $450.0K | 21,659 | SEC↗ |
| CRGX CARGO Therapeutics, Inc. | D To issuer deriv | 2025-08-19 | 2025-08-19 | 25,000 | — | $0 | 0 | SEC↗ |
| CBIO GLYCOMIMETICS INC | A Award deriv | 2025-06-23 | 2025-06-23 | 9,023 | — | $0 | 9,023 | SEC↗ |
| CRGX CARGO Therapeutics, Inc. | A Award deriv | 2025-06-18 | 2025-06-20 | 25,000 | — | $0 | 25,000 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2025-05-30 | 2025-06-03 | 35,000 | — | $0 | 35,000 | SEC↗ |
| ACLX Arcellx, Inc. | A Award deriv | 2025-05-29 | 2025-05-30 | 9,174 | — | $0 | 9,174 | SEC↗ |
| VOR Vor Biopharma Inc. | A Award deriv | 2025-05-22 | 2025-05-23 | 30,000 | — | $0 | 30,000 | SEC↗ |
| CRGX CARGO Therapeutics, Inc. | A Award deriv | 2024-06-04 | 2024-06-06 | 23,742 | — | $0 | 23,742 | SEC↗ |
| ACLX Arcellx, Inc. | A Award deriv | 2024-05-28 | 2024-06-06 | 8,011 | — | $0 | 8,011 | SEC↗ |
| VOR Vor Biopharma Inc. | A Award deriv | 2024-05-23 | 2024-05-28 | 30,000 | — | $0 | 30,000 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2024-05-22 | 2024-05-24 | 25,133 | — | $0 | 25,133 | SEC↗ |
| PNT POINT Biopharma Global Inc | D To issuer deriv | 2023-12-27 | 2023-12-27 | 44,749 | — | $0 | 0 | SEC↗ |
| PNT POINT Biopharma Global Inc | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,000 | — | $0 | 0 | SEC↗ |
| PNT POINT Biopharma Global Inc | D To issuer deriv | 2023-12-27 | 2023-12-27 | 25,614 | — | $0 | 0 | SEC↗ |
| PNT POINT Biopharma Global Inc | D To issuer | 2023-12-27 | 2023-12-27 | 3,600 | — | $0 | 0 | SEC↗ |
| PNT POINT Biopharma Global Inc | U Tender | 2023-12-26 | 2023-12-27 | 35,400 | — | $0 | 3,600 | SEC↗ |
| CRGX CARGO Therapeutics, Inc. | A Award deriv | 2023-11-09 | 2023-11-13 | 25,000 | — | $0 | 25,000 | SEC↗ |
| ACLX Arcellx, Inc. | A Award deriv | 2023-06-14 | 2023-06-16 | 11,459 | — | $0 | 11,459 | SEC↗ |
| PNT POINT Biopharma Global Inc | A Award deriv | 2023-06-01 | 2023-06-05 | 44,749 | — | $0 | 44,749 | SEC↗ |
| VOR Vor Biopharma Inc. | A Award deriv | 2023-05-26 | 2023-06-02 | 30,000 | — | $0 | 30,000 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2023-05-24 | 2023-05-25 | 24,900 | — | $0 | 24,900 | SEC↗ |
| PNT POINT Biopharma Global Inc | P Buy | 2022-11-23 | 2022-11-28 | 3,600 | $6.85 | $24.7K | 3,600 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2022-07-05 | 2022-07-06 | 7,222 | — | $0 | 7,222 | SEC↗ |
| VOR Vor Biopharma Inc. | A Award deriv | 2022-06-14 | 2022-06-16 | 16,911 | — | $0 | 16,911 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2022-06-03 | 2022-06-06 | 19,596 | — | $0 | 19,596 | SEC↗ |
| PNT POINT Biopharma Global Inc | A Award deriv | 2022-06-02 | 2022-06-06 | 25,614 | — | $0 | 25,614 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion deriv | 2022-02-08 | 2022-02-09 | 21,659 | — | $0 | 0 | SEC↗ |
| ACLX Arcellx, Inc. | C Conversion | 2022-02-08 | 2022-02-09 | 21,659 | — | $0 | 21,659 | SEC↗ |
| ACLX Arcellx, Inc. | A Award deriv | 2022-02-03 | 2022-02-07 | 61,538 | — | $0 | 61,538 | SEC↗ |
| GMTX Gemini Therapeutics, Inc. | A Award deriv | 2021-10-04 | 2022-03-09 | 0 | — | $0 | 0 | SEC↗ |
| GMTX Gemini Therapeutics, Inc. | A Award deriv | 2021-10-04 | 2021-10-06 | 17,245 | — | $0 | 17,245 | SEC↗ |
| PNT POINT Biopharma Global Inc | A Award deriv | 2021-07-06 | 2021-07-08 | 25,000 | — | $0 | 25,000 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2021-05-26 | 2021-05-27 | 19,596 | — | $0 | 19,596 | SEC↗ |
| GMTX Gemini Therapeutics, Inc. | A Award deriv | 2021-03-12 | 2022-03-09 | 17,529 | — | $0 | 17,529 | SEC↗ |
| GMTX Gemini Therapeutics, Inc. | A Award deriv | 2021-03-12 | 2021-03-15 | 25,000 | — | $0 | 25,000 | SEC↗ |
| GMTX Gemini Therapeutics, Inc. | A Award deriv | 2021-02-05 | 2021-04-07 | 58,855 | — | $0 | 58,855 | SEC↗ |
| VOR Vor Biopharma Inc. | A Award deriv | 2021-02-05 | 2021-02-09 | 16,900 | — | $0 | 16,900 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | C Conversion deriv | 2020-09-21 | 2020-09-23 | 177,872 | — | $0 | 0 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | C Conversion | 2020-09-21 | 2020-09-23 | 53,625 | — | $0 | 53,625 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | P Buy deriv | 2020-08-07 | 2020-09-23 | 177,872 | $2.81 | $499.8K | 177,872 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2020-07-31 | 2020-09-23 | 11,156 | — | $0 | 11,156 | SEC↗ |
| DYN Dyne Therapeutics, Inc. | A Award deriv | 2020-07-31 | 2020-09-23 | 14,444 | — | $0 | 14,444 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | D To issuer deriv | 2020-04-02 | 2020-04-03 | 115,572 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | D To issuer deriv | 2020-04-02 | 2020-04-03 | 92,283 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | D To issuer deriv | 2020-04-02 | 2020-04-03 | 28,571 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | D To issuer deriv | 2020-04-02 | 2020-04-03 | 112,500 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | D To issuer deriv | 2020-04-02 | 2020-04-03 | 62,500 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | D To issuer deriv | 2020-04-02 | 2020-04-03 | 10,416 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | D To issuer deriv | 2020-04-02 | 2020-04-03 | 133,000 | — | $0 | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | D To issuer | 2020-04-02 | 2020-04-03 | 15,622 | $48.00 | $749.9K | 0 | SEC↗ |
| NITE Nightstar Therapeutics plc | D To issuer deriv | 2019-06-07 | 2019-06-07 | 21,000 | $11.93 | $250.5K | 0 | SEC↗ |
| NITE Nightstar Therapeutics plc | D To issuer deriv | 2019-06-07 | 2019-06-07 | 18,200 | $13.23 | $240.8K | 0 | SEC↗ |
| NITE Nightstar Therapeutics plc | D To issuer | 2019-06-07 | 2019-06-07 | 29,124 | $25.50 | $742.7K | 0 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | M Exercise deriv | 2019-02-01 | 2019-02-05 | 10,417 | — | $0 | 20,833 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | A Award deriv | 2019-02-01 | 2019-02-05 | 133,000 | — | $0 | 133,000 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | F Tax w/h | 2019-02-01 | 2019-02-05 | 3,291 | $21.00 | $69.1K | 7,126 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | M Exercise | 2019-02-01 | 2019-02-05 | 10,417 | — | $0 | 10,417 | SEC↗ |
| NITE Nightstar Therapeutics plc | A Award deriv | 2019-01-25 | 2019-01-29 | 21,000 | — | $0 | 21,000 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | A Award deriv | 2018-02-01 | 2018-02-05 | 62,500 | — | $0 | 62,500 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | A Award deriv | 2018-02-01 | 2018-02-05 | 31,250 | — | $0 | 31,250 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | A Award deriv | 2017-02-01 | 2017-02-03 | 112,500 | — | $0 | 112,500 | SEC↗ |
| RARX Ra Pharmaceuticals, Inc. | A Award deriv | 2016-10-31 | 2016-10-31 | 29,285 | — | $0 | 29,285 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2015-08-14 | 2015-08-17 | 9,500 | — | $0 | 123,799 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2015-08-14 | 2015-08-17 | 9,500 | $7.94 | $75.4K | 78,770 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2015-08-14 | 2015-08-17 | 9,500 | $42.92 | $407.7K | 69,270 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2015-07-14 | 2015-07-15 | 1,701 | — | $0 | 133,299 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2015-07-14 | 2015-07-15 | 5,799 | — | $0 | 13,744 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2015-07-14 | 2015-07-15 | 1,701 | $7.94 | $13.5K | 76,770 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2015-07-14 | 2015-07-15 | 5,799 | $2.03 | $11.8K | 75,069 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2015-07-14 | 2015-07-15 | 7,500 | $48.92 | $366.9K | 69,270 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2015-06-15 | 2015-06-16 | 7,500 | — | $0 | 19,543 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2015-06-15 | 2015-06-16 | 7,500 | $41.67 | $312.5K | 69,270 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2015-06-15 | 2015-06-16 | 7,500 | $2.03 | $15.2K | 76,770 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2015-06-12 | 2015-06-16 | 10,000 | $41.29 | $412.9K | 69,270 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2015-05-14 | 2015-05-18 | 7,316 | — | $0 | 27,043 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2015-05-14 | 2015-05-18 | 7,684 | — | $0 | 0 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2015-05-14 | 2015-05-18 | 7,684 | $2.03 | $15.6K | 86,954 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2015-05-14 | 2015-05-18 | 7,684 | $39.28 | $301.8K | 79,270 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2015-05-14 | 2015-05-18 | 7,316 | $39.28 | $287.4K | 79,270 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2015-05-14 | 2015-05-18 | 7,316 | $2.03 | $14.9K | 86,586 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | A Award deriv | 2015-01-07 | 2015-01-09 | 100,000 | — | $0 | 100,000 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2014-06-17 | 2014-06-18 | 13,530 | $12.51 | $169.3K | 78,463 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2014-03-06 | 2014-03-10 | 4,510 | $13.65 | $61.6K | 91,993 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2014-02-12 | 2014-02-13 | 4,506 | $13.92 | $62.7K | 96,503 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2014-02-07 | 2014-02-11 | 33,295 | — | $0 | 7,684 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2014-02-07 | 2014-02-11 | 34,482 | — | $0 | 0 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise deriv | 2014-02-07 | 2014-02-11 | 20,614 | — | $0 | 34,359 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2014-02-07 | 2014-02-11 | 34,482 | $0.87 | $30.0K | 57,028 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2014-02-07 | 2014-02-11 | 33,295 | $2.03 | $67.6K | 90,323 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | S Sale | 2014-02-07 | 2014-02-11 | 9,928 | $14.22 | $141.2K | 101,009 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | M Exercise | 2014-02-07 | 2014-02-11 | 20,614 | $2.03 | $41.8K | 110,937 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | A Award deriv | 2014-01-08 | 2014-01-10 | 100,000 | — | $0 | 100,000 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | A Award deriv | 2013-05-15 | 2013-05-17 | 135,000 | — | $0 | 135,000 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | C Conversion deriv | 2013-03-25 | 2013-03-27 | 116,686 | — | $0 | 0 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | C Conversion deriv | 2013-03-25 | 2013-03-27 | 40,000 | — | $0 | 0 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | C Conversion deriv | 2013-03-25 | 2013-03-27 | 52,173 | — | $0 | 0 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | C Conversion deriv | 2013-03-25 | 2013-03-27 | 115,000 | — | $0 | 0 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | C Conversion | 2013-03-25 | 2013-03-27 | 4,023 | — | $0 | 22,546 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | C Conversion | 2013-03-25 | 2013-03-27 | 1,379 | — | $0 | 12,758 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | C Conversion | 2013-03-25 | 2013-03-27 | 1,799 | — | $0 | 14,557 | SEC↗ |
| TTPH TETRAPHASE PHARMACEUTICALS | C Conversion | 2013-03-25 | 2013-03-27 | 3,096 | — | $0 | 18,523 | SEC↗ |